Log in

LON:IQAIIQ-AI Share Price, Forecast & News

GBX 3.12
-0.12 (-3.70 %)
(As of 07/3/2020 04:00 PM ET)
Today's Range
Now: GBX 3.13
50-Day Range
MA: GBX 3.01
52-Week Range
Now: GBX 3.13
Volume75,000 shs
Average VolumeN/A
Market Capitalization£4.56 million
P/E RatioN/A
Dividend YieldN/A

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.46 out of 5 stars

Industry, Sector and Symbol

Industry N/A



Sales & Book Value

Annual Sales£267,868.00
Cash FlowGBX 0.61 per share
Book ValueGBX 1.20 per share



Market Cap£4.56 million
Next Earnings DateN/A
OptionableNot Optionable

Receive IQAI News and Ratings via Email

Sign-up to receive the latest news and ratings for IQAI and its competitors with MarketBeat's FREE daily newsletter.

IQ-AI (LON:IQAI) Frequently Asked Questions

How has IQ-AI's stock been impacted by COVID-19 (Coronavirus)?

IQ-AI's stock was trading at GBX 2.83 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, IQAI shares have increased by 10.6% and is now trading at GBX 3.13. View which stocks have been most impacted by Coronavirus.

Has IQ-AI been receiving favorable news coverage?

News coverage about IQAI stock has trended neutral this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. IQ-AI earned a coverage optimism score of 0.5 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 3.0 out of 10, meaning that recent press coverage is unlikely to have an impact on the stock's share price in the next several days. View the latest news about IQ-AI.

What other stocks do shareholders of IQ-AI own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IQ-AI investors own include Macerich (MAC), Merck & Co., Inc. (MRK), Pfizer (PFE), Scotts Miracle-Gro (SMG), Xilinx (XLNX), Arista Networks (ANET), Amgen (AMGN), Advanced Micro Devices (AMD), Akers Biosciences (AKER) and Aimmune Therapeutics (AIMT).

What is IQ-AI's stock symbol?

IQ-AI trades on the London Stock Exchange (LON) under the ticker symbol "IQAI."

How do I buy shares of IQ-AI?

Shares of IQAI and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is IQ-AI's stock price today?

One share of IQAI stock can currently be purchased for approximately GBX 3.13.

How big of a company is IQ-AI?

IQ-AI has a market capitalization of £4.56 million and generates £267,868.00 in revenue each year.

This page was last updated on 7/5/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.